CD274 and breast cancer: The PANACEA trial studied trastuzumab and pembrolizumab in patients with HER2-positive metastatic BC progressing on trastuzumab; PD-L1-positive patients showed a 15.2% objective response rate (ORR), while PD-L1-negative patients had 0%.